Zymeworks, a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of ...

For decades, the rate of spontaneous preterm birth in the United States has hovered stubbornly around 10%. Despite advancements in other areas of medicine, prematurity remains the second leading cause ...

Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...

Steering GenAi into the pharma fast lane; ASCO 2026 – translating emerging science into better patient outcomes; Welcoming ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

Mental health has been at the centre of our business since our inception. But that work doesn't just extend to our client ...